Analyze the Financials and Business Strategies of Industry Giants Dominating the Competitive Landscape: GlaxoSmithKline plc, ...

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in young children living in areas of higher deprivation from 2019 to 2023, ...

GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products (Zhifei), China's largest vaccine maker, to co-market its shingles vaccine Shingrix in ...

Teva Pharmaceutical Industries Ltd. ADR 0.84% $19.88B ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

GSK's vaccine has just hit the mark in a phase 3 ... according to Pfizer. For children younger than five years old in the US, the infection leads to approximately 2.1 million outpatient visits ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in ...

GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will commercialise GSK’s shingles vaccine, Shingrix, in ...